| Species |
Mouse |
| Protein Construction |
IGF1R/CD221 (Glu31-His936)_x000D_
Accession # Q60751 |
His |
| N-term |
C-term |
|
| Purity |
> 95% as determined by Bis-Tris PAGE |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized IGF1R/CD221, His, Mouse at 5μg/ml (100μl/well) on the plate can bind Human IGFI, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
80.72 kDa (alpha subunit) and 23.0 kDa (beta subunit) |
| Apparent Molecular Weight |
Due to furin cleavage and glycosylation, the protein migrates to 110-140 kDa(alpha subunit) and 50-65 kDa(beta subunit) based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
The type 1 IGF receptor (IGF1R) is a transmembrane tyrosine kinase that is frequently overexpressed by tumours, and mediates proliferation and apoptosis protection. IGF signalling also influences hypoxia signalling, protease secretion, tumour cell motility and adhesion, and thus can affect the propensity for invasion and metastasis. Therefore, the IGF1R is now an attractive anti-cancer treatment target. |
| Synonyms |
CD221; IGF1R; IGF-1R; IGF-I R; IGF-I receptor; IGFIR; IGFR; JTK13; MGC142170; MGC142172; MGC18216 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
